Madrigal Pharmaceuticals (MDGL) Share-based Compensation Growth (1y) (2011 - 2026)
Madrigal Pharmaceuticals (MDGL) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -40.86% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Madrigal Pharmaceuticals | 15.79 Bn | 15.56 Bn | - | 62.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62.52% |
| Dec 31, 2025 | -34,280.00% |
| Sep 30, 2025 | 5,596.67% |
| Jun 30, 2025 | 14.84% |
| Mar 31, 2025 | 5.17% |
| Dec 31, 2024 | 814.29% |
| Sep 30, 2024 | 105.83% |
| Jun 30, 2024 | -281.37% |
| Mar 31, 2024 | 76.91% |
| Jun 30, 2023 | 259.17% |
| Mar 31, 2023 | 50.46% |
| Jun 30, 2022 | -20.52% |
| Mar 31, 2022 | 22.65% |
| Dec 31, 2021 | -32.99% |
| Sep 30, 2021 | 297.96% |
| Jun 30, 2021 | -200.54% |
| Mar 31, 2021 | 25.79% |
| Dec 31, 2020 | -475.62% |
| Sep 30, 2020 | 2.24% |
| Jun 30, 2020 | -26.64% |